Skip to main content


Figure 1 | BMC Medicine

Figure 1

From: What if HIV were unable to develop resistance against a new therapeutic agent?

Figure 1

Potential evolution of HIV-1 following therapy of previously treatment-naïve individuals with integrase inhibitors. In rare cases, the emergence of resistance mutations in patients treated with raltegravir or elvitegravir can lead to virological failure (left). Virological failure with resistance mutations in treatment-naïve patients treated with dolutegravir has not been reported (right).

Back to article page